Correlation Between Loncar Cancer and Virtus LifeSci

Can any of the company-specific risk be diversified away by investing in both Loncar Cancer and Virtus LifeSci at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Loncar Cancer and Virtus LifeSci into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Loncar Cancer Immunotherapy and Virtus LifeSci Biotech, you can compare the effects of market volatilities on Loncar Cancer and Virtus LifeSci and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Loncar Cancer with a short position of Virtus LifeSci. Check out your portfolio center. Please also check ongoing floating volatility patterns of Loncar Cancer and Virtus LifeSci.

Diversification Opportunities for Loncar Cancer and Virtus LifeSci

0.89

Correlation Coefficient

Loncar Cancer  Virtus LifeSci

Very poor diversification

The 3 months correlation between Loncar and Virtus is 0.89. Overlapping area represents the amount of risk that can be diversified away by holding Loncar Cancer Immunotherapy and Virtus LifeSci Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Virtus LifeSci Biotech and Loncar Cancer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Loncar Cancer Immunotherapy are associated (or correlated) with Virtus LifeSci. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Virtus LifeSci Biotech has no effect on the direction of Loncar Cancer i.e., Loncar Cancer and Virtus LifeSci go up and down completely randomly.

Pair Corralation between Loncar Cancer and Virtus LifeSci

Given the investment horizon of 90 days Loncar Cancer Immunotherapy is expected to generate 0.96 times more return on investment than Virtus LifeSci. However, Loncar Cancer Immunotherapy is 1.04 times less risky than Virtus LifeSci. It trades about -0.13 of its potential returns per unit of risk. Virtus LifeSci Biotech is currently generating about -0.15 per unit of risk. If you would invest  1,217  in Loncar Cancer Immunotherapy on December 28, 2024 and sell it today you would lose (213.00) from holding Loncar Cancer Immunotherapy or give up 17.5% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Loncar Cancer Immunotherapy  vs.  Virtus LifeSci Biotech

Loncar Cancer Immuno

Risk-Adjusted Performance

Very Weak

Over the last 90 days Loncar Cancer Immunotherapy has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Etf's fundamental indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the ETF retail investors.

Virtus LifeSci Biotech

Risk-Adjusted Performance

Very Weak

Over the last 90 days Virtus LifeSci Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Etf's fundamental drivers remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the fund shareholders.

Pair Trading with Loncar Cancer and Virtus LifeSci

The main advantage of trading using opposite Loncar Cancer and Virtus LifeSci positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Loncar Cancer position performs unexpectedly, Virtus LifeSci can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Virtus LifeSci will offset losses from the drop in Virtus LifeSci's long position.

The idea behind Loncar Cancer Immunotherapy and Virtus LifeSci Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.